Yuko Takano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuko Takano has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
Yuichi Ando
Department of Clinical Oncology and Chemotherapy Nagoya University Hospital Nagoya Aichi Japan
6 shared publicationsToyone Kikumori
Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Japan
4 shared publicationsKei Koizumi
Department of Surgery 1, Division of Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
3 shared publications- Norikazu Masuda
Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
3 shared publications - Osamu Maeda
Department of Clinical Oncology and Chemotherapy Nagoya University Hospital Nagoya Japan
3 shared publications Sachi Morita
Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan
3 shared publications
Latest Publications
- 21 August 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (10) , 2095-2101
Pharmacotherapy for older adults with cancer: a digest of the Japanese clinical practice guidelines (second edition)—breast cancer
- 21 August 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (10) , 2095-2101
Pharmacotherapy for older adults with cancer: a digest of the Japanese clinical practice guidelines (second edition)—breast cancer
- Open Access
- 15 July 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1)
Comprehensive genomic profiling and tumor mutational burden in parathyroid carcinoma: a nationwide real-world study from Japan.
Parathyroid carcinoma (PC) is an extremely rare endocrine malignancy with limited treatment options for unresectable or recurrent cases. With the increasing use of comprehensive genomic profiling (CGP), treatment based on genomic findings is becoming more common. However, the frequency and clinical significance of elevated tumor mutational burden (TMB) in PC remain unclear because previous studies have been limited by small sample sizes. We retrospectively analyzed genomic and clinical data of patients with PC registered in the Center for Cancer Genomics and Advanced Therapeutics database in Japan between June 2019 and March 2025. TMB values were obtained as reported by each CGP assay. TMB-H was defined as TMB ≥ 10 mut/Mb for descriptive analyses. We also assessed genomic alterations, microsatellite instability (MSI) status, and clinicogenomic characteristics. Twenty-five patients with PC were included. The median assay-reported TMB was 4.0 mut/Mb (range, 0-35). Seven tumors (28.0%) had assay-reported TMB values of ≥ 10 mut/Mb, including three (12.0%) with TMB ≥ 20 mut/Mb. The most frequently altered genes were CDC73 (40%), TP53 (32%), and MEN1 (24%). No co-alterations were observed between CDC73 and MEN1 or between CDC73 and TP53. One tumor was MSI-high and was included in the TMB-H group. POLE alterations were detected in three cases, including two tumors in the TMB-H group. This nationwide, real-world study demonstrated that a subset of PCs showed elevated assay-reported TMB values and genomic features potentially related to abnormalities in DNA replication or repair pathways. These findings support the clinical relevance of comprehensive genomic profiling in identifying the molecular heterogeneity and potential therapeutic opportunities for this rare malignancy.
- 15 July 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1)
Open AccessComprehensive genomic profiling and tumor mutational burden in parathyroid carcinoma: a nationwide real-world study from Japan.
Parathyroid carcinoma (PC) is an extremely rare endocrine malignancy with limited treatment options for unresectable or recurrent cases. With the increasing use of comprehensive genomic profiling (CGP), treatment based on genomic findings is becoming more common. However, the frequency and clinical significance of elevated tumor mutational burden (TMB) in PC remain unclear because previous studies have been limited by small sample sizes. We retrospectively analyzed genomic and clinical data of patients with PC registered in the Center for Cancer Genomics and Advanced Therapeutics database in Japan between June 2019 and March 2025. TMB values were obtained as reported by each CGP assay. TMB-H was defined as TMB ≥ 10 mut/Mb for descriptive analyses. We also assessed genomic alterations, microsatellite instability (MSI) status, and clinicogenomic characteristics. Twenty-five patients with PC were included. The median assay-reported TMB was 4.0 mut/Mb (range, 0-35). Seven tumors (28.0%) had assay-reported TMB values of ≥ 10 mut/Mb, including three (12.0%) with TMB ≥ 20 mut/Mb. The most frequently altered genes were CDC73 (40%), TP53 (32%), and MEN1 (24%). No co-alterations were observed between CDC73 and MEN1 or between CDC73 and TP53. One tumor was MSI-high and was included in the TMB-H group. POLE alterations were detected in three cases, including two tumors in the TMB-H group. This nationwide, real-world study demonstrated that a subset of PCs showed elevated assay-reported TMB values and genomic features potentially related to abnormalities in DNA replication or repair pathways. These findings support the clinical relevance of comprehensive genomic profiling in identifying the molecular heterogeneity and potential therapeutic opportunities for this rare malignancy.
- Open Access
- 8 March 2026
- Published by Wiley in Cancer Science
- Vol. 117 (5) , 1422-1433
FOLFIRINOX vs. Gemcitabine/Nab‐Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C‐ CAT Database Study
The clinical impact of BRCA2 variants and tumor mutational burden (TMB) on first‐line regimen selection—FOLFIRINOX (FFX) versus gemcitabine plus nab‐paclitaxel (GnP)—for pancreatic ductal adenocarcinoma (PDAC) remains unclear. Using the Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) database, we analyzed patients with unresectable or recurrent PDAC treated with first‐line FFX or GnP. Overall survival (OS) and time to treatment failure (TTF) were compared, stratified by BRCA2 pathogenic variants (PVs) and TMB status. A total of 4356 patients were included. In the overall population, GnP was associated with superior adjusted OS compared with FFX (adjusted hazard ratio [HR] 0.90, p = 0.015), while TTF was comparable. In patients with BRCA2 PVs (3.3%), FFX demonstrated a significantly higher objective response rate (66.7% vs. 33.3%) and longer TTF compared with GnP. However, OS in patients with BRCA2 PVs was comparable between the two regimens (HR 1.11, p = 0.665). Among patients with BRCA2 PVs treated with GnP, OS was numerically longer with second‐line FFX than with nal‐IRI/5‐FU/leucovorin (HR 0.51; p = 0.119). In patients without BRCA2 PVs, OS was longer with GnP. TMB‐high status (2.9%) predicted significantly longer OS regardless of the first‐line regimen (HR 0.64, p < 0.001). In conclusion, GnP was associated with superior adjusted OS in the overall population. In BRCA2 PV tumors, greater tumor shrinkage with first‐line FFX did not translate into longer OS, underscoring the importance of sequencing strategies that ensure timely exposure to platinum‐based therapy. TMB‐high tumors may benefit from timely access to immunotherapy.
- 8 March 2026
- Published by Wiley in Cancer Science
- Vol. 117 (5) , 1422-1433
Open AccessFOLFIRINOX vs. Gemcitabine/Nab‐Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C‐ CAT Database Study
The clinical impact of BRCA2 variants and tumor mutational burden (TMB) on first‐line regimen selection—FOLFIRINOX (FFX) versus gemcitabine plus nab‐paclitaxel (GnP)—for pancreatic ductal adenocarcinoma (PDAC) remains unclear. Using the Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) database, we analyzed patients with unresectable or recurrent PDAC treated with first‐line FFX or GnP. Overall survival (OS) and time to treatment failure (TTF) were compared, stratified by BRCA2 pathogenic variants (PVs) and TMB status. A total of 4356 patients were included. In the overall population, GnP was associated with superior adjusted OS compared with FFX (adjusted hazard ratio [HR] 0.90, p = 0.015), while TTF was comparable. In patients with BRCA2 PVs (3.3%), FFX demonstrated a significantly higher objective response rate (66.7% vs. 33.3%) and longer TTF compared with GnP. However, OS in patients with BRCA2 PVs was comparable between the two regimens (HR 1.11, p = 0.665). Among patients with BRCA2 PVs treated with GnP, OS was numerically longer with second‐line FFX than with nal‐IRI/5‐FU/leucovorin (HR 0.51; p = 0.119). In patients without BRCA2 PVs, OS was longer with GnP. TMB‐high status (2.9%) predicted significantly longer OS regardless of the first‐line regimen (HR 0.64, p < 0.001). In conclusion, GnP was associated with superior adjusted OS in the overall population. In BRCA2 PV tumors, greater tumor shrinkage with first‐line FFX did not translate into longer OS, underscoring the importance of sequencing strategies that ensure timely exposure to platinum‐based therapy. TMB‐high tumors may benefit from timely access to immunotherapy.
- 6 November 2025
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 30 (12) , 2399-2409
Future perspective of clinical usefulness of metabolic and mitochondrial heterogeneity in triple-negative breast cancers
Triple-negative breast cancer (TNBC) is best characterized by high aggressiveness and significant biological heterogeneity. Although the current TNBC clinical trials include genomic biomarkers to stratify treatment arms, they are still limited by metabolic heterogeneity within TNBC subtypes. The metabolic reprogramming, a cancer hallmark, in TNBC involves adaptive regulation of glycolysis, lipid metabolism, and oxidative phosphorylation (OXPHOS), with distinct metabolic phenotypes significantly influencing tumor sensitivity to treatment. Mitochondrial heterogeneity exacerbates the metabolic diversity of TNBC, with its dynamic functional regulation closely linked to cellular energy metabolism and signaling pathway adaptation. Interplay between OXPHOS, metabolites, and immune activity creates a self-reinforcing mechanism where metabolic adaptations in TNBC cells not only support their energy demands but also actively construct an immune-privileged niche that shields tumors from immune surveillance and limits the efficacy of treatments. These mechanisms and mitochondrial diversity could be heterogeneous and specific to TNBC subtypes. Thus, metabolic phenotyping of TNBC subtypes could reveal previously unidentified patient subgroups, potentially explaining divergent survival outcomes and offering metabolism-targeted therapeutic strategies that might improve outcomes for patients who currently lack effective treatment alternatives.
- 6 November 2025
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 30 (12) , 2399-2409
Future perspective of clinical usefulness of metabolic and mitochondrial heterogeneity in triple-negative breast cancers
Triple-negative breast cancer (TNBC) is best characterized by high aggressiveness and significant biological heterogeneity. Although the current TNBC clinical trials include genomic biomarkers to stratify treatment arms, they are still limited by metabolic heterogeneity within TNBC subtypes. The metabolic reprogramming, a cancer hallmark, in TNBC involves adaptive regulation of glycolysis, lipid metabolism, and oxidative phosphorylation (OXPHOS), with distinct metabolic phenotypes significantly influencing tumor sensitivity to treatment. Mitochondrial heterogeneity exacerbates the metabolic diversity of TNBC, with its dynamic functional regulation closely linked to cellular energy metabolism and signaling pathway adaptation. Interplay between OXPHOS, metabolites, and immune activity creates a self-reinforcing mechanism where metabolic adaptations in TNBC cells not only support their energy demands but also actively construct an immune-privileged niche that shields tumors from immune surveillance and limits the efficacy of treatments. These mechanisms and mitochondrial diversity could be heterogeneous and specific to TNBC subtypes. Thus, metabolic phenotyping of TNBC subtypes could reveal previously unidentified patient subgroups, potentially explaining divergent survival outcomes and offering metabolism-targeted therapeutic strategies that might improve outcomes for patients who currently lack effective treatment alternatives.
- Open Access
- 23 June 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32 (5) , 1157-1158
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor–positive, HER2‑negative advanced or metastatic breast cancer
- 23 June 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32 (5) , 1157-1158
Open AccessCorrection: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor–positive, HER2‑negative advanced or metastatic breast cancer
- Open Access
- 20 May 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32 (4) , 841-856
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor–positive, HER2-negative advanced or metastatic breast cancer
Background: A cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) is a current standard first-/second-line treatment for hormone receptor (HR)-positive, HER2-negative advanced/metastatic breast cancer (AMBC). We aimed to provide real-world evidence regarding CDK4/6i therapy in this population. Methods: In this multicenter observational study, data from patients who had started CDK4/6i therapy between January 1, 2019, and December 31, 2021, as first-/second-line treatment for AMBC were used; real-world progression-free survival (rwPFS), chemotherapy-free survival, and overall survival were analyzed using the Kaplan–Meier method. Additionally, data were analyzed by separating patients with treatment-free interval (TFI) < 12 months (deemed resistant to ET) from the first-line treatment group (hereafter, the exclusive first-line treatment group). Results: Data from 745 patients were analyzed. Compared with palbociclib, abemaciclib was used in younger patients and those with expected poor prognosis. Median rwPFS was 36.8, 17.8, and 31.4 months in patients with de novo stage IV disease, TFI < 12 months, and TFI ≥ 12 months, respectively, in the first-line treatment group, and 17.4 months in the second-line treatment group. In the exclusive first-line treatment group, median rwPFS of the subsequent treatment after initial CDK4/6i plus ET was < 7 months, regardless of the type of subsequent treatment; prognosis was especially poor in those who were switched to chemotherapy. Conclusions: The real-world survival outcomes found in this study for patients receiving first-/second-line CDK4/6i therapy were consistent with those of randomized phase 3 studies. As outcomes of subsequent treatment after initial CDK4/6i plus ET remain insufficient, further improvement in treatment is necessary.
- 20 May 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32 (4) , 841-856
Open AccessReal-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor–positive, HER2-negative advanced or metastatic breast cancer
Background: A cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) is a current standard first-/second-line treatment for hormone receptor (HR)-positive, HER2-negative advanced/metastatic breast cancer (AMBC). We aimed to provide real-world evidence regarding CDK4/6i therapy in this population. Methods: In this multicenter observational study, data from patients who had started CDK4/6i therapy between January 1, 2019, and December 31, 2021, as first-/second-line treatment for AMBC were used; real-world progression-free survival (rwPFS), chemotherapy-free survival, and overall survival were analyzed using the Kaplan–Meier method. Additionally, data were analyzed by separating patients with treatment-free interval (TFI) < 12 months (deemed resistant to ET) from the first-line treatment group (hereafter, the exclusive first-line treatment group). Results: Data from 745 patients were analyzed. Compared with palbociclib, abemaciclib was used in younger patients and those with expected poor prognosis. Median rwPFS was 36.8, 17.8, and 31.4 months in patients with de novo stage IV disease, TFI < 12 months, and TFI ≥ 12 months, respectively, in the first-line treatment group, and 17.4 months in the second-line treatment group. In the exclusive first-line treatment group, median rwPFS of the subsequent treatment after initial CDK4/6i plus ET was < 7 months, regardless of the type of subsequent treatment; prognosis was especially poor in those who were switched to chemotherapy. Conclusions: The real-world survival outcomes found in this study for patients receiving first-/second-line CDK4/6i therapy were consistent with those of randomized phase 3 studies. As outcomes of subsequent treatment after initial CDK4/6i plus ET remain insufficient, further improvement in treatment is necessary.
- Open Access
- 2 May 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32 (4) , 816-825
Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast
Background: High tumor mutational burden (TMB-H) is an established biomarker for a favorable response to immune checkpoint inhibitors. However, tumor mutational burden (TMB) in invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) has not been sufficiently investigated. Methods: We collected data of patients with ILC or IDC from the Center for Cancer Genomics and Advanced Therapeutics database between June 2019 and August 2023. Furthermore, we examined the clinicopathological factors and TMB status. Results: Patients with ILC (n = 170) had a median TMB score of 4.00 mut/Mb (interquartile range, 2.00–7.14 mut/Mb), whereas those with IDC (n = 2598) had a score of 3.90 mut/Mb (2.00–6.00 mut/Mb). TMB-H was more common in patients with ILC than in those with IDC (18.2% vs. 10.1%, P < 0.001), particularly in the ER+ /HER2− subtype. Multivariate analysis revealed that the pathological diagnosis of ILC (P = 0.006), tissue samples collected from metastatic sites (P < 0.001), and older age (50 years, P < 0.001) were independent factors for TMB-H. Conclusions: Patients with ILC were more likely to have TMB-H than those with IDC. The findings of this study would be invaluable in selecting treatment strategies for patients with ILC.
- 2 May 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32 (4) , 816-825
Open AccessTumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast
Background: High tumor mutational burden (TMB-H) is an established biomarker for a favorable response to immune checkpoint inhibitors. However, tumor mutational burden (TMB) in invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) has not been sufficiently investigated. Methods: We collected data of patients with ILC or IDC from the Center for Cancer Genomics and Advanced Therapeutics database between June 2019 and August 2023. Furthermore, we examined the clinicopathological factors and TMB status. Results: Patients with ILC (n = 170) had a median TMB score of 4.00 mut/Mb (interquartile range, 2.00–7.14 mut/Mb), whereas those with IDC (n = 2598) had a score of 3.90 mut/Mb (2.00–6.00 mut/Mb). TMB-H was more common in patients with ILC than in those with IDC (18.2% vs. 10.1%, P < 0.001), particularly in the ER+ /HER2− subtype. Multivariate analysis revealed that the pathological diagnosis of ILC (P = 0.006), tissue samples collected from metastatic sites (P < 0.001), and older age (50 years, P < 0.001) were independent factors for TMB-H. Conclusions: Patients with ILC were more likely to have TMB-H than those with IDC. The findings of this study would be invaluable in selecting treatment strategies for patients with ILC.
- Open Access
- 10 April 2025
- Published by Springer Nature in Research Square
Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast
Background High tumor mutational burden (TMB-H) is an established biomarker for a favorable response to immune checkpoint inhibitors. However, tumor mutational burden (TMB) in invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) has not been sufficiently investigated. Methods We collected data of patients with ILC or IDC from the Center for Cancer Genomics and Advanced Therapeutics database between June 2019 and August 2023. Furthermore, we examined the clinicopathological factors and TMB status. Results Patients with ILC (n = 170) had a median TMB score of 4.00 mut/Mb (interquartile range, 2.00–7.14 mut/Mb), whereas those with IDC (n = 2,598) had a score of 3.90 mut/Mb (2.00–6.00 mut/Mb). TMB-H was more common in patients with ILC than in those with IDC (18.2% vs. 10.1%, P < 0.001), particularly in the ER+/HER2 − subtype. Multivariate analysis revealed that the pathological diagnosis of ILC (P = 0.006), tissue samples collected from metastatic sites (P < 0.001), and older age (50 years, P < 0.001) were independent factors for TMB-H. Conclusions Patients with ILC were more likely to have TMB-H than those with IDC. The findings of this study would be invaluable in selecting treatment strategies for patients with ILC.
- 10 April 2025
- Published by Springer Nature in Research Square
Open AccessTumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast
Background High tumor mutational burden (TMB-H) is an established biomarker for a favorable response to immune checkpoint inhibitors. However, tumor mutational burden (TMB) in invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) has not been sufficiently investigated. Methods We collected data of patients with ILC or IDC from the Center for Cancer Genomics and Advanced Therapeutics database between June 2019 and August 2023. Furthermore, we examined the clinicopathological factors and TMB status. Results Patients with ILC (n = 170) had a median TMB score of 4.00 mut/Mb (interquartile range, 2.00–7.14 mut/Mb), whereas those with IDC (n = 2,598) had a score of 3.90 mut/Mb (2.00–6.00 mut/Mb). TMB-H was more common in patients with ILC than in those with IDC (18.2% vs. 10.1%, P < 0.001), particularly in the ER+/HER2 − subtype. Multivariate analysis revealed that the pathological diagnosis of ILC (P = 0.006), tissue samples collected from metastatic sites (P < 0.001), and older age (50 years, P < 0.001) were independent factors for TMB-H. Conclusions Patients with ILC were more likely to have TMB-H than those with IDC. The findings of this study would be invaluable in selecting treatment strategies for patients with ILC.
- 23 August 2024
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (10) , 1093-1099
Status of incremental costs of first-line treatment recommended in Japanese clinical guidelines for metastatic breast cancer patients
Background: The increasing incidence and prevalence of breast cancer alongside diagnostic and treatment technology advances have produced a debate about the financial burden cancer places on the healthcare system and concerns about access. Methods: This study was conducted at 51 hospitals belonging to the Breast Cancer Study Group of the Japan Clinical Oncology Group using a web-based survey. The survey period conducted from July 2021 to June 2022. The study population included patients with metastatic breast cancer who received the related treatment as their first-line therapy. The proportion of patients who selected that regimen as their first-line treatment was tabulated. The total cost increase for each current standard therapy in comparison to conventional treatments was calculated. Results: A total of 702 patients (pts) were surveyed. Of those enrolled, 342 (48.7%) received high-cost treatment [estimated monthly drug costs exceeding ~500 000 Japanese Yen (JPY)]. Of these, 16 pts (4.7%) were receiving very high-cost treatment, amounting to more than 1 000 000 JPY per month. Fifty three (15.5%) of the patients who received high-cost treatment were 75 years of age or older. Of these, 1 pt (0.3%) were receiving very high-cost treatment. Analyses of incremental costs by current drugs showed that abemaciclib was costly with total additional cost of 6 365 670 JPY per patient. The total additional cost of the regimen per patient that included palbociclib was the second highest at 4011248 JPY, followed by atezolizumab at 3209033 JPY. Conclusions: The findings indicate that evaluating the financial implications of high-cost treatments requires considering not only drug prices but also analysis of total cost increase.
- 23 August 2024
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (10) , 1093-1099
Status of incremental costs of first-line treatment recommended in Japanese clinical guidelines for metastatic breast cancer patients
Background: The increasing incidence and prevalence of breast cancer alongside diagnostic and treatment technology advances have produced a debate about the financial burden cancer places on the healthcare system and concerns about access. Methods: This study was conducted at 51 hospitals belonging to the Breast Cancer Study Group of the Japan Clinical Oncology Group using a web-based survey. The survey period conducted from July 2021 to June 2022. The study population included patients with metastatic breast cancer who received the related treatment as their first-line therapy. The proportion of patients who selected that regimen as their first-line treatment was tabulated. The total cost increase for each current standard therapy in comparison to conventional treatments was calculated. Results: A total of 702 patients (pts) were surveyed. Of those enrolled, 342 (48.7%) received high-cost treatment [estimated monthly drug costs exceeding ~500 000 Japanese Yen (JPY)]. Of these, 16 pts (4.7%) were receiving very high-cost treatment, amounting to more than 1 000 000 JPY per month. Fifty three (15.5%) of the patients who received high-cost treatment were 75 years of age or older. Of these, 1 pt (0.3%) were receiving very high-cost treatment. Analyses of incremental costs by current drugs showed that abemaciclib was costly with total additional cost of 6 365 670 JPY per patient. The total additional cost of the regimen per patient that included palbociclib was the second highest at 4011248 JPY, followed by atezolizumab at 3209033 JPY. Conclusions: The findings indicate that evaluating the financial implications of high-cost treatments requires considering not only drug prices but also analysis of total cost increase.
- 1 April 2024
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 13 (3) , 184-188
Long-term response to MEK inhibitor monotherapy in a patient with papillary thyroid carcinoma harboring BRAF V600E mutation
Solid tumors harboring mutations in the Braf gene (BRAF) are currently treated by combination Braf/MEK inhibitor therapy, and there is an extensive literature on patient response rates. Alternatively, few studies have documented the clinical response of BRAF mutation-positive solid tumors to MEK inhibitor monotherapy. We report the case of a 57-year-old female diagnosed with papillary thyroid carcinoma and progressive lung metastases initially treated by total thyroidectomy and subsequent thyroid-stimulating hormone suppression therapy. Next-generation sequencing revealed that the tumor harbored a BRAFV600E mutation, and the patient was enrolled in a clinical study of the oral MEK1/2 inhibitor binimetinib. Shortly after starting treatment, the patient experienced pneumothorax due to rapid regression of lung metastases, and computed tomography after 6 months of binimetinib treatment revealed a partial sustained response. One year later, the dose was reduced because of an acneiform rash. After 5 years of binimetinib treatment, lung metastases had regrown, and treatment was switched to the oral multikinase inhibitor lenvatinib. This case demonstrates the potential of MEK inhibitor monotherapy as an alternative treatment for BRAF mutation-positive papillary thyroid carcinoma.
- 1 April 2024
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 13 (3) , 184-188
Long-term response to MEK inhibitor monotherapy in a patient with papillary thyroid carcinoma harboring BRAF V600E mutation
Solid tumors harboring mutations in the Braf gene (BRAF) are currently treated by combination Braf/MEK inhibitor therapy, and there is an extensive literature on patient response rates. Alternatively, few studies have documented the clinical response of BRAF mutation-positive solid tumors to MEK inhibitor monotherapy. We report the case of a 57-year-old female diagnosed with papillary thyroid carcinoma and progressive lung metastases initially treated by total thyroidectomy and subsequent thyroid-stimulating hormone suppression therapy. Next-generation sequencing revealed that the tumor harbored a BRAFV600E mutation, and the patient was enrolled in a clinical study of the oral MEK1/2 inhibitor binimetinib. Shortly after starting treatment, the patient experienced pneumothorax due to rapid regression of lung metastases, and computed tomography after 6 months of binimetinib treatment revealed a partial sustained response. One year later, the dose was reduced because of an acneiform rash. After 5 years of binimetinib treatment, lung metastases had regrown, and treatment was switched to the oral multikinase inhibitor lenvatinib. This case demonstrates the potential of MEK inhibitor monotherapy as an alternative treatment for BRAF mutation-positive papillary thyroid carcinoma.